TNF and interstitial lung disease: Dixon et al. [14] observed incident ILD in 2.8 % of patients receiving anti-TNFα agents, whereas Koike et al. [23] and Takeuchi et al. [24] reported rates of 0.6 % and 0.5 %, respectively.